Education
About Us
Working with TipRanks
Follow Us
IceCure Medical (ICCM)
NASDAQ:ICCM
ICCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.47 - $1.63
Previous CloseN/A
Volume318.06K
Average Volume (3M)1.82M
Market Cap
$69.38M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Aug 18, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding68,693,054
10 Day Avg. Volume4,677,269
30 Day Avg. Volume1,816,104
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.75Price Target Upside172.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PositionIceCure's cash position is bolstered by a recent $10M rights offering, providing sufficient capital for operations into early 2Q26.
Market PotentialProSense cryoablation procedure has the potential to replace lumpectomy for the target patient population of approximately 65,000 annually in the U.S.
Regulatory ApprovalThe FDA Medical Device Advisory Committee Panel gave a favorable recommendation for ICCM's ProSense System, with nine panelists voting in favor, indicating a positive outcome for IceCure.
Bears Say
Financial StrainThe company may need to raise additional capital, highlighting potential financial strain.
Revenue DeclineThe company's revenue for 4Q24 declined by 30% year-over-year, missing the projection of $1.2M.
Revenue EstimatesAnalysts are lowering 2025 and 2026 revenue estimates and widening 2025 and 2026 GAAP loss per share expectations.
Icecure Medical News
ICCM FAQ
What was IceCure Medical’s price range in the past 12 months?
IceCure Medical lowest stock price was $0.47 and its highest was $1.63 in the past 12 months.
What is IceCure Medical’s market cap?
IceCure Medical’s market cap is $69.38M.
When is IceCure Medical’s upcoming earnings report date?
IceCure Medical’s upcoming earnings report date is Aug 18, 2025 which is in 15 days.
How were IceCure Medical’s earnings last quarter?
IceCure Medical released its earnings results on May 28, 2025. The company reported -$0.059 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.019.
Is IceCure Medical overvalued?
According to Wall Street analysts IceCure Medical’s price is currently Undervalued.
Does IceCure Medical pay dividends?
IceCure Medical does not currently pay dividends.
What is IceCure Medical’s EPS estimate?
IceCure Medical’s EPS estimate is -0.06.
How many shares outstanding does IceCure Medical have?
IceCure Medical has 68,693,054 shares outstanding.
What happened to IceCure Medical’s price movement after its last earnings report?
IceCure Medical reported an EPS of -$0.059 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -9.009%.
Which hedge fund is a major shareholder of IceCure Medical?
Currently, no hedge funds are holding shares in ICCM
Icecure Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (172.28% Upside)
$2.75 (172.28% Upside)
Blogger Sentiment
Bullish
ICCM Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
55.38%
12-Months-Change
Fundamentals
Return on Equity
-173.47%
Trailing 12-Months
Asset Growth
-30.83%
Trailing 12-Months
Company Description
IceCure Medical
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
ICCM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted positive developments with the FDA and interest from the medical community, as well as regional sales growth in North America and Europe. However, the company continues to face challenges with overall revenue and profit margins declining, and it remains in a net loss position. Financial support from a major shareholder provides some stability as they await regulatory decisions.Read More>ICCM Stock 12 Month Forecast
Average Price Target
$2.75
▲(172.28%Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
<0.01% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---